Literature DB >> 30468915

KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.

Matteo Bassetti1, Novella Carannante2, Carlo Pallotto3, Elda Righi1, Giovanni Di Caprio4, Mariano Bernardo5, Giuseppe Sodano5, Enza Mallardo5, Daniela Francisci6, Assunta Sartor1, Elena Graziano1, Carlo Tascini2.   

Abstract

OBJECTIVES: KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonisation is a major risk factor for developing systemic infection. Ceftazidime/avibactam (CAZ/AVI) may have a role as decolonisation therapy in special situations.
METHODS: This was a retrospective, observational, multicentre study. The KPC-Kp gut decolonisation rate of CAZ/AVI-based therapy (Group A) was compared with other antimicrobial regimens (Group B) in patients with KPC-Kp infection.
RESULTS: Among 12 patients in Group A, 11 (91.7%) achieved gut decolonisation. None of the 24 patients of Group B were decolonised.
CONCLUSION: CAZ/AVI-based therapy could be useful in KPC-Kp gut decolonisation in high-risk patients.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase-producing Klebsiella pneumoniae; Ceftazidime; Ceftazidime/avibactam; Gut decolonisation; KPC

Mesh:

Substances:

Year:  2018        PMID: 30468915     DOI: 10.1016/j.jgar.2018.11.014

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  2 in total

1.  Gastrointestinal colonization by OXA-48-producing Enterobacterales: risk factors for persistent carriage.

Authors:  O Lima; A Sousa; A Filgueira; M Carmen González-Novoa; Celina Domínguez-López; M Ávila-Nuñez; M Represa; P Rubiñán; L Martínez-Lamas; Sonia Pérez-Castro; M Rubianes; M T Pérez-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-07       Impact factor: 5.103

Review 2.  Ceftazidime-avibactam.

Authors:  M Matesanz; J Mensa
Journal:  Rev Esp Quimioter       Date:  2021-09-30       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.